Pfizer discussing high Allergan break-up fee

Pfizer Inc is said to be discussing a break-up fee of 2 to 3% of the value of its $150 billion possible acquisition of Allergan Plc, Reuters reports, quoting sources familiar with the matter.

This would be one of the highest break-up fees ever because the merger between the two pharmaceutical companies would be one of the biggest ones ever, the story notes.

Read more here.